Stocks
Exact Sciences CorporationEXAS
NASDAQHealthcareBiotechnology$103.57+0.29%
A molecular diagnostics company focused on early cancer detection, best known for its Cologuard colorectal cancer screening test. The firm combines DNA and biomarker analysis with clinical risk factors to improve diagnostic accuracy, attracting investor attention as a leader in non-invasive cancer testing.
Market Cap: $19.8B52W Range: $38.81 – $103.75
Congressional Interest in Exact Sciences Corporation (EXAS)
7 members of Congress have disclosed 34 trades in Exact Sciences Corporation (EXAS), a Healthcare company. The buy/sell breakdown shows 16 purchases versus 18 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
34
Unique Politicians
7
Buys
16
Sells
18
Who in Congress Is Trading EXAS?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-24 | Kevin Hern | sell | $1K – $15K |
| 2024-05-10 | Josh Gottheimer | sell | $1K – $15K |